HIGHLIGHTS
- who: Jan Buitelaar from the Technion Institute of The of, Australia have published the paper: Toward Precision Medicine in ADHD, in the Journal: (JOURNAL)
- future: Work in this direction including out of sample validation is needed. As classical study designs are poor at addressing ADHD heterogeneity future clinical studies using novel designs e_g stepped-care designs are also required as to complement to the more standard efficacy RCTs (Lenze et_al 2020). Because prior studies of these biomarkers have focused on group effects rather than on diagnostic accuracy and individual prediction more work is needed to . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.